Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Other Operating Expenses (2016 - 2023)

Historic Other Operating Expenses for Celldex Therapeutics (CLDX) over the last 14 years, with Q4 2023 value amounting to -$12.5 million.

  • Celldex Therapeutics' Other Operating Expenses changed N/A to -$12.5 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$12.5 million, marking a year-over-year change of. This contributed to the annual value of -$12.5 million for FY2023, which is 1666.67% up from last year.
  • According to the latest figures from Q4 2023, Celldex Therapeutics' Other Operating Expenses is -$12.5 million.
  • Celldex Therapeutics' 5-year Other Operating Expenses high stood at $5.1 million for Q2 2020, and its period low was -$15.0 million during Q2 2022.
  • Over the past 5 years, Celldex Therapeutics' median Other Operating Expenses value was -$234000.0 (recorded in 2020), while the average stood at -$1.3 million.
  • As far as peak fluctuations go, Celldex Therapeutics' Other Operating Expenses skyrocketed by 123888.89% in 2021, and later crashed by 490000.0% in 2022.
  • Over the past 5 years, Celldex Therapeutics' Other Operating Expenses (Quarter) stood at -$318000.0 in 2019, then skyrocketed by 94.34% to -$18000.0 in 2020, then skyrocketed by 1238.89% to $205000.0 in 2021, then tumbled by 7417.07% to -$15.0 million in 2022, then grew by 16.67% to -$12.5 million in 2023.
  • Its last three reported values are -$12.5 million in Q4 2023, -$15.0 million for Q2 2022, and $536000.0 during Q1 2022.